136 related articles for article (PubMed ID: 38194625)
21. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
22. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
van Oers MH; Van Glabbeke M; Giurgea L; Klasa R; Marcus RE; Wolf M; Kimby E; van t Veer M; Vranovsky A; Holte H; Hagenbeek A
J Clin Oncol; 2010 Jun; 28(17):2853-8. PubMed ID: 20439641
[TBL] [Abstract][Full Text] [Related]
23. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
25. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
26. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Bachy E; Houot R; Morschhauser F; Sonet A; Brice P; Belhadj K; Cartron G; Audhuy B; Fermé C; Feugier P; Sebban C; Delwail V; Maisonneuve H; Le Gouill S; Lefort S; Brousse N; Foussard C; Salles G;
Haematologica; 2013 Jul; 98(7):1107-14. PubMed ID: 23645690
[TBL] [Abstract][Full Text] [Related]
28. Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.
Kenkre VP; Hong F; Cerhan JR; Lewis M; Sullivan L; Williams ME; Gascoyne RD; Horning SJ; Kahl BS
Clin Cancer Res; 2016 Feb; 22(4):821-6. PubMed ID: 26510856
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
[TBL] [Abstract][Full Text] [Related]
31. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
32. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
33. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
34. Pros and cons of rituximab maintenance in follicular lymphoma.
Zhang L; Ghielmini M; Cheson BD; Ujjani C
Cancer Treat Rev; 2017 Jul; 58():34-40. PubMed ID: 28628883
[TBL] [Abstract][Full Text] [Related]
35. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
36. Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Itchaki G; Gafter-Gvili A; Lahav M; Vidal L; Raanani P; Shpilberg O; Paul M
Cochrane Database Syst Rev; 2013 Jul; (7):CD008909. PubMed ID: 23832787
[TBL] [Abstract][Full Text] [Related]
37. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
38. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
[No Abstract] [Full Text] [Related]
39. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
[TBL] [Abstract][Full Text] [Related]
40. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
